ACAD · Acadia Pharmaceuticals Inc
$28.24
-0.14 (-0.49%)
At close · Aug 14
Market Cap
$4.87B
Shares
172.31M
Acadia Pharmaceuticals Inc Earnings Call Transcripts
Every quarterly earnings call for Acadia Pharmaceuticals Inc (ACAD) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼0.7%
$130.71M
−$27.18M
'22 Q3
22-11-02
▲4.4%
$136.49M
−$41.73M
'22 Q4
23-02-28
▲2.6%
$118.46M
−$43.02M
'23 Q1
23-05-08
▲22.8%
$165.24M
$1.11M
'23 Q2
23-07-18
▲62%
$211.70M
−$65.18M
'23 Q3
23-11-02
▲69.3%
$231.04M
$45.80M
'23 Q4
24-02-27
▲73.8%
$205.83M
$16.55M
'24 Q1
24-05-08
▲46.4%
$241.96M
$33.39M
'24 Q2
24-08-06
▲18.3%
$250.40M
$32.77M
'24 Q3
24-11-06
▲12.4%
$259.60M
$143.74M
'24 Q4
25-02-26
▲18.7%
$244.32M
$18.99M
'25 Q1
25-05-07
▲9.3%
$264.57M
$26.67M
'25 Q2
25-08-06
▲11.3%
$278.63M
$71.78M
'25 Q3
25-11-05
▲9.4%
$283.99M
$273.57M
'25 Q4
26-02-25
▲9.7%
$268.06M
$3.64M
'26 Q1
26-05-06
LATEST
▲16.4%
$307.96M
$31.50M
'26 Q2
26-08-04
Conference
Investor event
2026-08-12
Canaccord Genuity's 46th Annual Growth Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
Revenue
$307.96M
▲ 16.4% YoY Diluted EPS
$0.18
▲ 12.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-06
Acadia Pharmaceuticals Inc Q1 FY2026 Earnings Call
Confident tone
DAYBUE Commercial Performance and STIX Launch
Remlifanserin Pipeline in Alzheimer's Disease Psychosis
NUPLAZID Franchise Dynamics
Revenue
$268.06M
▲ 9.7% YoY Diluted EPS
$0.02
▼ 81.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Acadia Pharmaceuticals Inc Q4 FY2025 Earnings Call
Confident tone
DAYBUE growth and STIX launch
NUPLAZID commercial momentum and 2026 guidance
Remlifanserin (ACP-204) Phase II readout
Revenue
$283.99M*
▲ 9.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Acadia Pharmaceuticals Inc Q3 FY2025 Earnings Call
Confident tone
DAYBUE commercial momentum
NUPLAZID record performance and field force expansion
IRA / pricing risk on NUPLAZID
Revenue
$278.63M
▲ 11.3% YoY Diluted EPS
$0.42
▲ 110% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Acadia Pharmaceuticals Inc Q2 FY2025 Earnings Call
Confident tone
DAYBUE commercial momentum
NUPLAZID growth and DTC campaign
Pipeline and R&D Day
Revenue
$264.57M
▲ 9.3% YoY Diluted EPS
$0.16
▼ 20% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Acadia Pharmaceuticals Inc Q1 FY2025 Earnings Call
Confident tone
DAYBUE commercial momentum and growth outlook
DAYBUE geographic expansion (Europe and rest of world)
NUPLAZID Parkinson's disease psychosis franchise
Revenue
$244.32M
▲ 18.7% YoY Diluted EPS
$0.11
▲ 10% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Acadia Pharmaceuticals Inc Q4 FY2024 Earnings Call
Confident tone
NUPLAZID commercial performance
2025 revenue guidance
Pipeline breadth and R&D Day
Revenue
$259.60M*
▲ 12.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Acadia Pharmaceuticals Inc Q3 FY2024 Earnings Call
Confident tone
DAYBUE commercial performance
NUPLAZID commercial performance
ACP-204 (Alzheimer's disease psychosis)
Revenue
$250.40M
▲ 18.3% YoY Diluted EPS
$0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Acadia Pharmaceuticals Inc Q2 FY2024 Earnings Call
Positive tone
DAYBUE commercial performance
NUPLAZID franchise and growth
Prader-Willi syndrome program (ACP-101)
Revenue
$241.96M
▲ 46.4% YoY Diluted EPS
$0.20
▲ 1900% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Acadia Pharmaceuticals Inc Q1 FY2024 Earnings Call
Positive tone
DAYBUE commercial performance
NUPLAZID franchise growth
Pipeline and late-stage development
Revenue
$205.83M
▲ 73.8% YoY Diluted EPS
$0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Acadia Pharmaceuticals Inc Q4 FY2023 Earnings Call
Confident tone
DAYBUE launch and growth
Pipeline and R&D
NUPLAZID commercial franchise
Revenue
$231.04M
▲ 69.3% YoY Diluted EPS
$0.28
Gross margin
92.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Acadia Pharmaceuticals Inc Q3 FY2023 Earnings Call
Revenue
$211.70M
▲ 62% YoY Diluted EPS
$-0.40
Gross margin
93.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-18
Acadia Pharmaceuticals Inc Q2 FY2023 Earnings Call
Revenue
$165.24M
▲ 22.8% YoY Diluted EPS
$0.01
Gross margin
95.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Acadia Pharmaceuticals Inc Q1 FY2023 Earnings Call
Revenue
$118.46M
▲ 2.6% YoY Diluted EPS
$-0.27
Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Acadia Pharmaceuticals Inc Q4 FY2022 Earnings Call
Revenue
$136.49M
▲ 4.4% YoY Diluted EPS
$-0.26
Gross margin
98.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Acadia Pharmaceuticals Inc Q3 FY2022 Earnings Call
Revenue
$130.71M
▼ 0.7% YoY Diluted EPS
$-0.17
Gross margin
98.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Acadia Pharmaceuticals Inc Q2 FY2022 Earnings Call
Revenue
$134.56M
▲ 16.8% YoY Diluted EPS
$-0.21
Gross margin
98.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Acadia Pharmaceuticals Inc Q1 FY2022 Earnings Call
Revenue
$115.47M
▲ 8.4% YoY Diluted EPS
$-0.70
Gross margin
97.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Acadia Pharmaceuticals Inc Q4 FY2021 Earnings Call
Revenue
$130.76M
▲ 8.1% YoY Diluted EPS
$-0.27
Gross margin
98.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Acadia Pharmaceuticals Inc Q3 FY2021 Earnings Call
Revenue
$131.61M
▲ 9.2% YoY Diluted EPS
$-0.09
Gross margin
97.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Acadia Pharmaceuticals Inc Q2 FY2021 Earnings Call
Revenue
$115.22M
▲ 4.6% YoY Diluted EPS
$-0.27
Gross margin
97.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Acadia Pharmaceuticals Inc Q1 FY2021 Earnings Call
Revenue
$106.55M
▲ 18.3% YoY Diluted EPS
$-0.42
Gross margin
97.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Acadia Pharmaceuticals Inc Q4 FY2020 Earnings Call
Revenue
$121.01M
▲ 23.1% YoY Gross margin
97.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Acadia Pharmaceuticals Inc Q3 FY2020 Earnings Call
Revenue
$120.58M
▲ 27.5% YoY Gross margin
98.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Acadia Pharmaceuticals Inc Q2 FY2020 Earnings Call
Revenue
$110.10M
▲ 32.3% YoY Gross margin
97.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Acadia Pharmaceuticals Inc Q1 FY2020 Earnings Call
Revenue
$90.07M
▲ 43.1% YoY Gross margin
96.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–27 of 27 earnings calls
Key facts
CIK
1070494
CUSIP
004225108
13F (30d)
351 filings
323 filers
Visit website
Investor relations